Skip to main content
Top
Published in: Rheumatology International 12/2020

01-12-2020 | Magnetic Resonance Imaging | Observational Research

Bone turnover biomarkers, disease activity, and MRI changes of sacroiliac joints in patients with spondyloarthritis

Authors: Oleg Iaremenko, Iuliia Shynkaruk, Dmytro Fedkov, Kateryna Iaremenko, Liubov Petelytska

Published in: Rheumatology International | Issue 12/2020

Login to get access

Abstract

The lack of valid biomarkers in patients with spondyloarthritis (SpA) requires searching for additional options to increase sacroiliac joint (SIJ) evaluation effectiveness. We assessed the serum levels of bone turnover markers and their relationships with active and chronic changes in SIJs using magnetic resonance imaging (MRI), indices, and laboratory parameters of disease activity in SpA patients. 102 patients with SpA and 15 healthy subjects were included. Testing of serum levels of transforming growth factor-beta (TGF-β1), Wnt3, sclerostin, and Dickkopf-1 (Dkk-1) was conducted. Active inflammatory lesions in SIJs were evaluated using Spondyloarthritis Research Consortium of Canada (SPARCC) MRI SIJ score, and chronic changes using the Danish scoring method. Bath Ankylosing Spondylitis Disease Activity Index, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), Ankylosing Spondylitis Disease Activity Scores with CRP, and ESR were used to assess disease activity. Serum levels of Dkk-1, TGF-β1, and sclerostin were significantly lower in SpA patients compared to healthy controls. The serum levels of Dkk-1 positively correlated with CRP. Dkk-1 had a significant negative correlation with Danish score. The sclerostin serum level had a weak negative correlation with the active inflammatory MRI SIJ lesions. There were positive correlations between TGF-β1 and sclerostin with Dkk-1, and negative correlation between Wnt3 and sclerostin. Dkk-1 positively correlated with CRP and negatively with chronic SIJ changes by Danish score. Sclerostin negatively correlated with the active SIJ lesions by SPARCC. This suggests that Dkk-1 and sclerostin are the most promising candidates to reveal inflammation and bone turnover in patients with SpA.
Literature
4.
go back to reference Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych W (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225. https://doi.org/10.1002/art.30393CrossRef Chiowchanwisawakit P, Lambert RG, Conner-Spady B, Maksymowych W (2011) Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 63(8):2215–2225. https://​doi.​org/​10.​1002/​art.​30393CrossRef
5.
go back to reference Maksymowych W, Chiowchanwisawakit P, Lambert R (2010) TNF blocking agents promote resolution of structural lesions in patients with spondyloarthritis. Ann Rheum Dis 69:262 Maksymowych W, Chiowchanwisawakit P, Lambert R (2010) TNF blocking agents promote resolution of structural lesions in patients with spondyloarthritis. Ann Rheum Dis 69:262
14.
go back to reference Sieper J, Appel H, Rudwaleit M et al (2010) Inverse correlation between serum levels of dickkopf 1 (DKK 1), and new bone formation in ankylosing spondylitis patients. Ann Rheum Dis 69(3):442 Sieper J, Appel H, Rudwaleit M et al (2010) Inverse correlation between serum levels of dickkopf 1 (DKK 1), and new bone formation in ankylosing spondylitis patients. Ann Rheum Dis 69(3):442
17.
go back to reference Ustun N, Tok F, Kalyoncu U et al (2014) Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol Port 39(2):146–151 Ustun N, Tok F, Kalyoncu U et al (2014) Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta Reumatol Port 39(2):146–151
20.
go back to reference Roberts AB, Sporn MB (1990) Peptide growth factors and their receptors. In: Handbook of experimental pharmakology. Springer-Verlag, New York Roberts AB, Sporn MB (1990) Peptide growth factors and their receptors. In: Handbook of experimental pharmakology. Springer-Verlag, New York
32.
go back to reference Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291 Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291
42.
go back to reference Weber U, Zubler V, Zhao Z et al (2015) Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 74(6):985–992CrossRef Weber U, Zubler V, Zhao Z et al (2015) Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 74(6):985–992CrossRef
Metadata
Title
Bone turnover biomarkers, disease activity, and MRI changes of sacroiliac joints in patients with spondyloarthritis
Authors
Oleg Iaremenko
Iuliia Shynkaruk
Dmytro Fedkov
Kateryna Iaremenko
Liubov Petelytska
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04708-z

Other articles of this Issue 12/2020

Rheumatology International 12/2020 Go to the issue

Acknowledgement to Referees

Acknowledgement to referees

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.